Yucai Wang

Aug 11, 2024 | nature.com | Razan Mohty |Radhika Bansal |Urshila Durani |Madiha Iqbal |Yucai Wang |Jonas Paludo | +8 more

Dear Editor,Hemophagocytic lymphohistiocytosis (HLH) is a rare complication of chimeric antigen receptor T-cell (CAR-T) therapy [1,2,3]. With the increasing use of CAR-T therapy in treating hematological malignancies, the unique phenomenon of CAR-T-associated HLH (carHLH) is increasingly recognized. Albeit rare, reported rates vary from 1–3% to 35% depending on the underlying disease, patient population and the CAR-T product [1,2,3].

Jul 30, 2024 | mdpi.com | Yucai Wang |Jin Zhao

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Dec 12, 2023 | obroncology.com | Yucai Wang

OBR: What did your study examine, and what were the key clinical takeaways? Yucai Wang, MD, PhD: The study we were trying to do was to examine the outcomes of mantle cell lymphoma (MCL) following frontline bendamustine-rituximab (BR) therapy and second-line Bruton tyrosine kinase (BTK) inhibitor therapy. This is a retrospective multicenter study where we collaborated among 26 centers looking at patients who received first-line BR with optional maintenance rituximab between 2014 and 2020.

Aug 17, 2023 | nature.com | William Breen |Jason Young |Radhika Bansal |N. Nora Bennani |Jonas Paludo |Yucai Wang | +2 more

AbstractPET/CT is used to evaluate relapsed/refractory non-Hodgkin lymphoma (NHL) prior to chimeric antigen receptor T-cell (CAR-T) infusion at two time points: pre-leukapheresis (pre-leuk) and pre-lymphodepletion chemotherapy (pre-LD). We hypothesized that changes in PET/CT between these time points predict outcomes after CAR-T.